{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:15:48Z","timestamp":1790673348179,"version":"4.1.0"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004756","name":"Emil Aaltosen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["2018"],"award-info":[{"award-number":["2018"]}],"id":[{"id":"10.13039\/501100004756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010711","name":"Sy\u00f6p\u00e4s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["2017"],"award-info":[{"award-number":["2017"]}],"id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004092","name":"Kuopion Yliopistollinen Sairaala","doi-asserted-by":"publisher","award":["2018"],"award-info":[{"award-number":["2018"]}],"id":[{"id":"10.13039\/501100004092","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008723","name":"Suomen L\u00e4\u00e4ketieteen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["2015"],"award-info":[{"award-number":["2015"]}],"id":[{"id":"10.13039\/100008723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004092","name":"Kuopion Yliopistollinen Sairaala","doi-asserted-by":"publisher","award":["2013"],"award-info":[{"award-number":["2013"]}],"id":[{"id":"10.13039\/501100004092","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Antiangiogenic therapy, although part of standard treatment in ovarian cancer, has variable efficacy. Furthermore, little is known about the prognostic biomarkers and factors influencing angiogenesis in cancer tissue. We evaluated the expression of angiopoietin-2 and two endothelial tyrosine kinase receptors, Tie-1 and Tie-2, and assessed their value in the prediction of survival in patients with malignant epithelial ovarian cancer. We also compared the expression of these factors between primary high grade serous tumors and their distant metastasis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Materials and methods<\/jats:title>\n<jats:p>We evaluated 86 women with primary epithelial ovarian cancer. Matched distal omental metastasis were investigated in 18.6% cases (N = 16). The expression levels of angiogenic factors were evaluated by immunohistochemistry in 306 specimens and by qRT-PCR in 111 samples.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A high epithelial expression level of Tie-2 is a significant prognostic factor in primary high grade serous ovarian cancer. It predicted significantly shorter overall survival both in univariate (p&lt;0.001) and multivariate survival analyses (p = 0.022). Low angiopoietin-2 expression levels in primary ovarian tumors were significantly associated with shorter overall survival (p = 0.015) in the univariate survival analysis. A low expression of angiopoietin-2 was also significantly related to high grade tumors, size of residual tumor after primary surgery and the recurrence of cancer (p = 0.008; p = 0.012; p = 0.018) in the whole study population. The expression of angiopoietin-2 and Tie-2 was stronger in distal omental metastasis than in primary high grade serous tumors in matched-pair analysis (p = 0.001; p = 0.002).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The angiogenic factor, angiopoietin-2, and its receptor Tie-2 seem to be significant prognostic factors in primary epithelial ovarian cancer. Their expression levels are also increased in metastatic lesions in comparison with primary tumors.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0241484","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T18:40:30Z","timestamp":1604601630000},"page":"e0241484","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["High expression of Tie-2 predicts poor prognosis in primary high grade serous ovarian cancer"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3996-6211","authenticated-orcid":true,"given":"Minna","family":"Sopo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Sallinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsi","family":"H\u00e4m\u00e4l\u00e4inen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annukka","family":"Kivel\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7593-2708","authenticated-orcid":true,"given":"Seppo","family":"Yl\u00e4-Herttuala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veli-Matti","family":"Kosma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leea","family":"Keski-Nisula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarit","family":"Anttila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,11,5]]},"reference":[{"key":"pone.0241484.ref001","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.molmed.2011.01.015","article-title":"VEGF and angiopoietin signaling in tumor angiogenesis and metastasis","volume":"17","author":"P Saharinen","year":"2011","journal-title":"Trends in Molecular Medicine"},{"key":"pone.0241484.ref002","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1186\/1471-2407-14-696","article-title":"Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer","volume":"14","author":"H Sallinen","year":"2014","journal-title":"BMC Cancer"},{"key":"pone.0241484.ref003","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1158\/1535-7163.MCT-10-0213","article-title":"Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1\/2-Neutralizing Peptibody","volume":"9","author":"A Coxon","year":"2010","journal-title":"Molecular cancer therapeutics"},{"key":"pone.0241484.ref004","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"LA Torre","year":"2015","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"pone.0241484.ref005","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A Randomized Clinical Trial of Cisplatin\/Paclitaxel Versus Carboplatin\/Paclitaxel as First-Line Treatment of Ovarian Cancer","volume":"95","author":"A du Bois","year":"2003","journal-title":"Journal of the National Cancer Institute"},{"key":"pone.0241484.ref006","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"RA Burger","year":"2011","journal-title":"The New England journal of medicine"},{"key":"pone.0241484.ref007","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"TJ Perren","year":"2011","journal-title":"The New England journal of medicine"},{"key":"pone.0241484.ref008","doi-asserted-by":"crossref","first-page":"i33","DOI":"10.1093\/annonc\/mdw093","article-title":"Anti-angiogenic agents in ovarian cancer: past, present, and future","volume":"27","author":"BJ Monk","year":"2016","journal-title":"Annals of Oncology"},{"key":"pone.0241484.ref009","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1470-2045(14)70244-X","article-title":"Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial","volume":"15","author":"BJ Monk","year":"2014","journal-title":"Lancet Oncology"},{"key":"pone.0241484.ref010","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2174\/1574892810999150827153642","article-title":"Angiogenesis Markers in Gynecological Tumors and Patents for Anti- Angiogenic Approach: Review","volume":"10","author":"DR Abdalla","year":"2015","journal-title":"Recent Patents on Anti-Cancer Drug Discovery"},{"key":"pone.0241484.ref011","first-page":"1498","article-title":"Preoperative Angiopoietin-2 Serum Levels: A Marker of Malignant Potential in Ovarian Neoplasms and Poor Prognosis in Epithelial Ovarian Cancer","volume":"20","author":"H Sallinen","year":"2010","journal-title":"International Journal of Gynecological Cancer"},{"key":"pone.0241484.ref012","first-page":"3403","article-title":"Tumor-derived Vascular Endothelial Growth Factor Up-Regulates Angiopoietin-2 in Host Endothelium and Destabilizes Host Vasculature, Supporting Angiogenesis in Ovarian Cancer","volume":"63","author":"L Zhang","year":"2003","journal-title":"Cancer Research"},{"key":"pone.0241484.ref013","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1756-9966-30-31","article-title":"Expression of Ets-1, Ang-2 and maspin in ovarian cancer and their role in tumor angiogenesis","volume":"30","author":"Z Lin","year":"2011","journal-title":"Journal of experimental & clinical cancer research: CR"},{"key":"pone.0241484.ref014","first-page":"1063","article-title":"The universal overexpression of a cancer testis antigen hiwi is associated with cancer angiogenesis","volume":"23","author":"S Li","year":"2010","journal-title":"Oncology reports"},{"key":"pone.0241484.ref015","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/j.ajpath.2014.05.006","article-title":"Angiopoietins Promote Ovarian Cancer Progression by Establishing a Procancer Microenvironment","volume":"184","author":"MK Brunckhorst","year":"2014","journal-title":"American Journal of Pathology"},{"key":"pone.0241484.ref016","volume-title":"WHO Classification of Tumours series\u2014volume IV","author":"AM Hanby","year":"2004"},{"key":"pone.0241484.ref017","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1186\/s12885-019-5757-3","article-title":"Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer","volume":"19","author":"M Sopo","year":"2019","journal-title":"BMC cancer"},{"key":"pone.0241484.ref018","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/TP.0b013e31829854d5","article-title":"Renal Ischemia-Reperfusion Induces Release of Angiopoietin-2 From Human Grafts of Living and Deceased Donors","volume":"96","author":"D de Vries","year":"2013","journal-title":"Transplantation Journal"},{"key":"pone.0241484.ref019","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12967-017-1307-4","article-title":"Metastatic pathway and the microvascular and physicochemical microenvironments of human melanoma xenografts","volume":"15","author":"R Huang","year":"2017","journal-title":"Journal of Translational Medicine"},{"key":"pone.0241484.ref020","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/en.2012-1105","article-title":"Angiopoietins\/TIE2 system and VEGF are involved in ovarian function in a DHEA rat model of polycystic ovary syndrome","volume":"153","author":"D Abramovich","year":"2012","journal-title":"Endocrinology"},{"key":"pone.0241484.ref021","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/jcp.2008.063859","article-title":"VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection","volume":"62","author":"K Engels","year":"2009","journal-title":"Journal of clinical pathology"},{"key":"pone.0241484.ref022","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/cvr\/cvt148","article-title":"The effects of VEGF-A on atherosclerosis, lipoprotein profile, and lipoprotein lipase in hyperlipidaemic mouse models","volume":"99","author":"SE Heinonen","year":"2013","journal-title":"Cardiovascular research"},{"key":"pone.0241484.ref023","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3748\/wjg.v10.i9.1382","article-title":"Expression and significance of angiopoietin-2 in gastric cancer","volume":"10","author":"XD Sun","year":"2004","journal-title":"World J Gastroenterol"},{"key":"pone.0241484.ref024","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1158\/0008-5472.CAN-06-4100","article-title":"Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrin-mediated pathway","volume":"67","author":"Y Imanishi","year":"2007","journal-title":"Cancer research"},{"key":"pone.0241484.ref025","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jhep.2004.01.027","article-title":"Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma","volume":"40","author":"T Torimura","year":"2004","journal-title":"Journal of Hepatology"},{"key":"pone.0241484.ref026","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3393\/ac.2017.33.1.9","article-title":"Expressions and clinical significances of Angiopoietin-1, Angiopoietin-2, and Tie-2 receptor in patients with colorectal cancer","volume":"33","author":"S Hong","year":"2017","journal-title":"Annals of coloproctology"},{"key":"pone.0241484.ref027","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1038\/sj.onc.1203035","article-title":"New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF","volume":"18","author":"J Holash","year":"1999","journal-title":"Oncogene"},{"key":"pone.0241484.ref028","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/0008-5472.CAN-12-2064","article-title":"Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition","volume":"73","author":"C Daly","year":"2013","journal-title":"Cancer research"},{"key":"pone.0241484.ref029","first-page":"8027","article-title":"Overexpression of Tie2 is associated with poor prognosis in patients with gastric cancer","volume":"15","author":"W Yang","year":"2018","journal-title":"Oncology letters"},{"key":"pone.0241484.ref030","first-page":"391","article-title":"Tie2\/Tek expression in breast carcinoma: Correlations of immunohistochemical assays and long-term follow-up in a series of 909 patients","volume":"22","author":"J Dales","year":"2003","journal-title":"International Journal of Oncology"},{"key":"pone.0241484.ref031","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/IGC.0000000000000973","article-title":"Combined Gene Therapy Using AdsVEGFR2 and AdsTie2 With Chemotherapy Reduces the Growth of Human Ovarian Cancer and Formation of Ascites in Mice","volume":"27","author":"L Tuppurainen","year":"2017","journal-title":"International Journal of Gynecologic Cancer"},{"key":"pone.0241484.ref032","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-015-0321-5","article-title":"Apoptosis, autophagy, necroptosis, and cancer metastasis","volume":"14","author":"Z Su","year":"2015","journal-title":"Mol Cancer"},{"key":"pone.0241484.ref033","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ygyno.2018.11.033","article-title":"The fallopian tube, \u201cprecursor escape\u201d and narrowing the knowledge gap to the origins of high-grade serous carcinoma","volume":"152","author":"TR Soong","year":"2019","journal-title":"Gynecologic Oncology"},{"key":"pone.0241484.ref034","doi-asserted-by":"crossref","first-page":"15885","DOI":"10.3390\/ijms140815885","article-title":"Angiogenesis-related pathways in the pathogenesis of ovarian cancer","volume":"14","author":"NG Gavalas","year":"2013","journal-title":"Int J Mol Sci"},{"key":"pone.0241484.ref035","doi-asserted-by":"crossref","first-page":"12705","DOI":"10.18632\/oncotarget.24061","article-title":"Ang-2 promotes lung cancer metastasis by increasing epithelial-mesenchymal transition","volume":"9","author":"Z Dong","year":"2018","journal-title":"Oncotarget"},{"key":"pone.0241484.ref036","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.celrep.2015.08.024","article-title":"The Orphan Receptor Tie1 Controls Angiogenesis and Vascular Remodeling by Differentially Regulating Tie2 in Tip and Stalk Cells","volume":"12","author":"S Savant","year":"2015","journal-title":"Cell Reports"},{"key":"pone.0241484.ref037","first-page":"1745","article-title":"Tie-1 Protein Tyrosine Kinase: A Novel Independent Prognostic Marker for Gastric Cancer","volume":"5","author":"W Lin","year":"1999","journal-title":"Clinical Cancer Research"},{"key":"pone.0241484.ref038","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen","volume":"30","author":"E Van Cutsem","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"pone.0241484.ref039","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2016.07.112","article-title":"Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2","volume":"143","author":"BJ Monk","year":"2016","journal-title":"Gynecologic Oncology"},{"key":"pone.0241484.ref040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejca.2016.09.004","article-title":"ENGOT-ov-6\/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer","volume":"70","author":"C Marth","year":"2016","journal-title":"European Journal of Cancer"},{"key":"pone.0241484.ref041","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S1470-2045(19)30178-0","article-title":"Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3\/ENGOT-ov2\/GOG-3001): a randomised, double-blind, phase 3 trial","volume":"20","author":"I Vergote","year":"2019","journal-title":"The Lancet Oncology"},{"key":"pone.0241484.ref042","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2018.08.036","article-title":"Exploratory outcome analyses according to stage and\/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer","volume":"152","author":"MA Gonz\u00e1lez","year":"2019","journal-title":"Gynecologic Oncology"},{"key":"pone.0241484.ref043","first-page":"JCO1901009","article-title":"Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer","author":"KS Tewari","year":"2019","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"pone.0241484.ref044","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/bjc.2016.194","article-title":"Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab","volume":"115","author":"C Zhou","year":"2016","journal-title":"The British Journal of Cancer"},{"key":"pone.0241484.ref045","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1038\/s41467-018-07174-1","article-title":"Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer","volume":"9","author":"GC Jayson","year":"2018","journal-title":"Nature communications"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0241484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T18:41:46Z","timestamp":1604601706000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0241484"}},"subtitle":[],"editor":[{"given":"Elizabeth","family":"Christie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,11,5]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0241484","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,5]]}}}